EVO Evotec Group Expected net earnings per share growth this year

EVO (evotec.com) - company brandmark

The shift in year-over-year EPS figures demonstrates a trend supported by the synergy of top chemists and biologists. -137.30 indicates the current profit level, which is based on unique IT drug discovery and rigorous standards. Evotec SE (EVO) ensures a stable cash flow through multi-year agreements with biotech leaders, which mitigates potential risks of declining business margins.

Net earnings per share growth this year: Evotec AG (EVO) for 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for Evotec SE (EVO)

- share price and expert price forecast:
Price Evotec Group|EVO - Price Target Chart
- market capitalization data:
Market Capitalization Evotec|EVO - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Evotec|EVO - Company Net Assets|Market Value to Book Value Ratio evotec.com|EVO - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Capital Evotec SE|EVO - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Evotec|EVO - Company Aggregate Debts|Debts to Book Value Evotec|EVO - Company Long-Term Debts|Company Current Liabilities Evotec|Intermediate Coverage Ratio evotec.com
- company profitability and valuation multiples indicators:
EVO - Company Net Income|Company Profit Forecast Evotec SE|EVO - P/E Multiple|Projected Price to Earnings Ratio Evotec SE|EVO - PEG Multiple|Company Value to EBITDA Evotec AG|EVO - Operating profit before deduction of amortization|Earnings per share for the last twelve months Evotec|EVO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months evotec.com|EVO - Earnings per share growth in current year|Net earnings per share change forecast for next year Evotec SE
- company sales and revenue statistics:
EVO - Revenue and Sales Volume|Company Future Revenue Evotec Corp|EVO - P/S Multiple|Forward P/S Multiple Evotec SE
Fundamental valuation:EVO Evotec Corp
Signature product of Evotec Group

Investors assess the resilience of Evotec SE (EVO) through earnings per share dynamics, which, given the moderate cyclicality of the R&D sector, allow for the isolation of venture capital volatility from the long-term innovation trend. When analyzing the annual evolution of earnings per share, it is essential to note that this percentage growth captures real capitalization efficiency, separating fundamental revenue growth from one-time accounting adjustments.

Direct competitors

IQV: Net earnings per one share growth for the current year|Earnings per share growth in current year Labcorp Holdings Inc.|MEDP (medpace.com) - Net earnings per one share growth for the current year|Earnings per share growth in current year ICON Public Limited Company (ICLR)|Net earnings per share growth this year Charles River CRL|Earnings growth in current year FTRE (Fortrea)|Lifecore - Earnings per share growth in current year|OABI - Earnings per share growth in current year|NOTV (inotivco.com) - Earnings per share growth this year|CDMO: Earnings growth in current year|CTLT: Net earnings per one share growth for the current year|Earnings per share growth in current year NightHawk Biosciences